Senti Biosciences Holdings, Inc. (SNTI): R&D Expense

Annual figures by period end, from SEC filings.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2022-12-31 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

$37.59M

Year ended 2025-12-31

$31.32M

Trailing 12 months to 2026-06-30

+10.1%

3-year compound annual growth

2021-12-31 R&D Expense (USD) 2025-12-31

Period ended	R&D Expense	Change YoY	Source filing
2025-12-31	$37.59M	+9.4%	2026-03-27, From 2025-01-01
2024-12-31	$34.36M	+6.9%	2026-03-27, From 2024-01-01
2023-12-31	$32.15M	+14.2%	2025-03-20, From 2023-01-01
2022-12-31	$28.14M	n/c	2024-03-21, From 2022-01-01
2021-12-31	$21.96M	n/a	2023-03-22, From 2021-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	R&D Expense	Change YoY
Senti Biosciences Holdings, Inc. (SNTI)	2025-12-31	$37.59M	+9.4%
Entera Bio Ltd. (ENTX)	2025-12-31	$6.00M	+33.5%
Inmune Bio, Inc. (INMB)	2025-12-31	$20.66M	-37.7%
Creative Medical Technology Holdings, Inc. (CELZ)	2025-12-31	$2.26M	-5.9%
AIM ImmunoTech Inc. (AIM)	2025-12-31	$3.92M	-36.7%
VivoSim Labs, Inc. (VIVS)	2026-03-31	$4.19M	-16.6%
Zivo Bioscience, Inc. (ZIVO)	2024-12-31	$3.13M	+127.7%
aTYR PHARMA INC (ATYR)	2025-12-31	$60.22M	+10.8%
Cardiff Oncology, Inc. (CRDF)	2025-12-31	$35.33M	-4.1%

Compare SNTI, ENTX, INMB, CELZ side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗